Meeting
2022 ASCO Annual Meeting
An immune-related gene expression profile to predict the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study.
Authors
Alessandra Boccaccino
Department of Translational Research and New Technologies in Medicine and Surgery-Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Alessandra Boccaccino , Robert Seitz , Mirella Giordano , Daniele Rossini , Margherita Ambrosini , Lisa Salvatore , Kimberly McGregor , Francesca Bergamo , Veronica Conca , Leonardo Provenzano , Stefano Tamberi , Matteo Ramundo , Giampaolo Tortora , Cosimo Rasola , Douglas Teller Ross , Alessandro Passardi , Tyler J. Nielsen , Matthew Gordon Varga , Chiara Cremolini , Carlotta Antoniotti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3581)
DOI
10.1200/JCO.2022.40.16_suppl.3581
Abstract #
3581
Poster Bd #
375
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.
First Author: Federica Marmorino
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2020 Gastrointestinal Cancers Symposium
A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610).
First Author: Caio Max Sao Pedro Rocha Lima
Poster
2020 Gastrointestinal Cancers Symposium
Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.
First Author: Akihito Tsuji